May 25, 2022
This week, Biomedical Advanced Research and Development Authority (BARDA) director Gary Disbrow, PhD, issued the 2022-26 BARDA Strategic Plan, which outlines the agency’s plan to further secure the nation during public health emergencies.
The plan is built around four strategic goals:
Each goal is supported by critical objectives. Of particular interest to the AABB community, BARDA will launch new efforts to address emerging infectious diseases and prioritize strategies to develop proven technologies for vaccines, therapeutics and diagnostics.
As part of its effort to promote interventions across the continuum of care, BARDA will also engage with stakeholders to inform MCM development to treat trauma and radiation injuries (including next-generation blood products) from nuclear threats.
The report also includes a summary of the agency’s COVID-19 response efforts and an overview of key legislation. AABB encourages members to view the entire strategic plan.